Franz von Nussbaum - Concepedia

Author

Franz von Nussbaum

Also Known As

F. Nussbaum, F. von Nussbaum, Franz Von Nussbaum, Franz von Nussbaum, Franz von Nussbaum., Franz von Nussbaum, Von Nussbaum, F., von Nussbaum, F., von Nussbaum, Franz

177

Publications

3.5K

Citations

H-Index

Concepts

All Affiliations

Bayer (Germany)Ludwig-Maximilians-Universität München Bayer (United States)AiCuris (Germany)Columbia University

About

Franz von Nussbaum is an author at Bayer (Germany) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	21	911
2	Natural Sciences	12	12	490
3	Biochemistry	11	11	429
4	Engineering	3	3	88
5	Health Sciences	1	1	45

Franz von Nussbaum

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction R.C. Hillig, Brice Sautier, Jens Schroeder, Proceedings of the National Academy of Sciences	2019	363
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage–Inducing or Repair–Compromising Therapies in Preclinical Cancer Models Antje M. Wengner, Gerhard Siemeister, Ulrich Lücking, Molecular Cancer Therapeutics	2019	200
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer Ulrich Lücking, Arne Scholz, Philip Lienau, ChemMedChem	2017	176
A Rapid Total Synthesis of Spirotryprostatin B: Proof of Its Relative and Absolute Stereochemistry Franz von Nussbaum, Samuel J. Danishefsky Angewandte Chemie International Edition Bioorganic ChemistryMolecular BiologyChemical BiologyMedicinal ChemistryNucleic Acid Chemistry	2000	117
Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity Antje M. Wengner, Gerhard Siemeister, Marcus Koppitz, Molecular Cancer Therapeutics OncologyMedicinePotent Antitumor ActivityMolecular BiologyImmune Checkpoint Inhibitor	2016	117
Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors <i>In Vitro</i> and <i>In Vivo</i> Gerhard Siemeister, Anne Mengel, Amaury E. Fernández‐Montalván, Clinical Cancer Research	2018	75
Probing the catalytic functions of Bub1 kinase using the small molecule inhibitors BAY-320 and BAY-524 Anna P. Baron, Conrad von Schubert, Fabien Cubizolles, eLife Molecular BiologyCell CycleSpindle Assembly CheckpointSignaling PathwayReceptor Tyrosine Kinase	2016	68
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models Ulrich Lücking, Lars Wortmann, Antje M. Wengner, Journal of Medicinal Chemistry	2020	68
Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer Ulrich Lücking, Dirk Kosemund, Niels Böhnke, Journal of Medicinal Chemistry Lead Optimization EffortsOncologyNovel TherapyPharmacologyImmunology	2021	68
Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85‐8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases Franz von Nussbaum, Volkhart M.‐J. Li, Swen Allerheiligen, ChemMedChem	2015	66

Page 1